vision problems semaglutide linked to increased risk of loss in diabetes patients How Does Semaglutide Affect Eye

For people with type 2 diabetes and obesity, guidelines increasingly favor choosing GLP-1-based agents early in the treatment regimen, particularly when weight and cardiorenal risk are central goals

Two additional Phase 3 oral assets are particularly useful to watch because they represent next entrants rather than franchise conversions: HDM1002 (conveglipron) HDM1002 is being positioned publicly as a selective oral small-molecule GLP-1R agonist for type 2 diabetes and obesity

Bone Age Relative to Chronological Age For patients with bone age measurements after at least 1 year of treatment (n = 56), bone age was delayed at baseline by a mean of 2.8 years (SD = 1.7) compared with chronological age (3.9 years [SD = 2.9] versus 6.7 years [SD = 3.8], respectively)

10.1093/hmg/ddt301 Hum

1991, 54: 113S-118S

Glutathione is widely known as the master antioxidant because of its central role in protecting cells from oxidative stress